Takeda Earnings Call: R&D Wins Amid Revenue Pressure

Takeda Pharmaceutical Company ((TAK)) has held its Q3 earnings call. Read on for the main highlights of the call.

Takeda Balances R&D Wins and Cash Strength Against Near-Term Revenue Drag

Takeda Pharmaceutical’s latest earnings call struck a cautiously optimistic tone: management highlighted a string of high‑impact late‑stage R&D wins and robust cash generation that buttress the company’s long‑term growth story, even as near‑term revenues are pressured by U.S. generic competition, policy headwinds and softer demand in parts of the plasma business. While investors face a period of top‑line and margin friction, the call underscored that pipeline progress and disciplined cost control are helping Takeda absorb these shocks without sacrificing core profitability.

Late-Stage R&D Success — Three Positive Phase III Readouts

Takeda put its innovation engine at the center of the narrative, spotlighting three positive Phase III outcomes in 2025 that management framed as future growth pillars. Oveporexton for excessive daytime sleepiness delivered particularly strong data, with about 85% of patients reaching normative Epworth Sleepiness Scale scores and statistically significant improvements across 14 endpoints; an NDA has already been submitted. Rusfertide showed durable hematocrit control below 45% through 52 weeks with better patient‑reported outcomes, also now at the NDA stage. Zasocitinib, a psoriasis candidate, posted rapid efficacy with PASI75 achieved within four weeks, more than half of patients reaching PASI90 at week 16, and around 30% achieving PASI100. Regulatory preparations for zasocitinib are underway, with management guiding to a launch in the first half of calendar 2027, reinforcing visibility on the medium‑term product cycle.

Growth & Launch Portfolio Now Over Half of Revenue

Management underscored that Takeda’s portfolio is steadily tilting toward newer assets: growth and launch products now represent more than 50% of total sales and grew 6.7% at constant exchange rates year‑to‑date, an acceleration from roughly 5% growth in earlier quarters. This shift is central to Takeda’s investment case, as it helps offset erosion in mature brands such as VYVANSE. The performance of the growth cohort signals that the company’s strategy of focusing capital and commercial resources on select high‑value assets is gaining traction, even in a challenging pricing and reimbursement environment.

ENTYVIO Maintains Momentum with Strong U.S. Access

ENTYVIO remained a key growth driver, posting 7.4% year‑to‑date growth at constant exchange rates and reinforcing its role as a cornerstone of Takeda’s GI franchise. The subcutaneous formulation, ENTYVIO Pen, secured formulary inclusion with all three major U.S. pharmacy benefit managers and now enjoys commercial coverage above 80%. Management reiterated that this access profile leaves the franchise on track to meet its full‑year growth target of about 6%. The call framed ENTYVIO as both a current growth engine and a strategic asset, even as the product faces longer‑term pricing risk under U.S. policy changes.

Strong Free Cash Flow and Upgraded FCF Outlook

Takeda’s cash generation was a clear bright spot. Adjusted free cash flow reached JPY 625.9 billion for the period, despite a sizeable upfront payment of USD 1.2 billion tied to the Innovent Biologics collaboration. The strength of free cash flow prompted management to upgrade its full‑year adjusted FCF outlook, positioning the company with ample financial flexibility to fund late‑stage launches, business development, and shareholder returns. For investors, this underlines the resilience of Takeda’s cash engine at a time when headline revenue and profit growth are under pressure.

Core Profitability Preserved Despite Revenue Headwinds

While Takeda lowered its revenue outlook due to intensified generic erosion of ADHD drug VYVANSE, it notably kept full‑year guidance for core operating profit and core EPS unchanged. Management now expects a low single‑digit revenue decline at constant exchange rates, but emphasized that disciplined operating expense control and cost efficiencies have so far insulated core profitability. This message is critical to the equity story: even as the top line shrinks modestly, Takeda is defending its margin profile while still investing behind upcoming launches.

Updated Financial Guidance and FX-Driven Upside

The revised full‑year guidance pegs revenue at JPY 4.53 trillion, core operating profit at JPY 1.15 trillion and core EPS at JPY 486. Management cited foreign exchange tailwinds and operational momentum as providing modest upside versus prior expectations, adding roughly JPY 30 billion to revenue and JPY 20 billion to core OP. These FX benefits, combined with cost discipline, are helping offset the drag from VYVANSE’s loss of exclusivity and other headwinds, allowing Takeda to reaffirm its core earnings targets while navigating what management repeatedly described as a transition year.

Vaccine and Selected Product Growth Stand Out

Within the broader portfolio, several products delivered standout growth that supports the shift toward newer assets. Dengue vaccine QDENGA accelerated to 22.1% growth, driven largely by continued uptake in Brazil. In plasma‑derived therapies, subcutaneous immunoglobulin products grew at a double‑digit rate, helping lift overall IG sales by 4.3% year‑to‑date. FRUZAQLA also continued to expand as its global rollout progresses. These pockets of high growth illustrate a more diversified set of contributors emerging beneath the headline numbers, partially offsetting slower or pressured legacy brands.

Strategic Pipeline Expansion via Innovent Collaboration

The tie‑up with Innovent Biologics featured prominently as a strategic move to deepen Takeda’s oncology pipeline. The deal brings in two oncology assets, TAK‑928 and TAK‑921, which have shown encouraging early clinical signals and will be developed globally under a shared investment framework. For TAK‑928, the companies have a 60/40 cost split, and the collaboration includes staged go/no‑go decision points to manage development risk. Management framed the partnership as a capital‑efficient way to broaden its late‑stage oncology footprint while preserving balance sheet strength.

Top-Line Decline Reflects VYVANSE LOE Pressure

Takeda’s reported numbers underscored the scale of the challenge from loss of exclusivity. For the first nine months, revenue was just over JPY 3.4 trillion, down 3.3% year‑on‑year, or 2.8% at constant exchange rates, with management explicitly citing VYVANSE generics as the primary driver. The erosion from this single asset is masking the underlying growth in newer products, a dynamic that investors will watch closely as they assess how quickly the emerging portfolio can close the gap left by the fading blockbuster.

Core Operating Profit Compression Amid Transition

Core operating profit for the nine‑month period came in at JPY 971.6 billion, a 3.4% year‑on‑year decline at both reported and constant exchange rates. Again, VYVANSE’s loss of exclusivity was identified as the main factor, despite visible efforts to trim operating expenses and drive efficiencies. The modest compression signals that while Takeda is managing costs aggressively, it cannot fully offset the profit headwind from its shrinking ADHD franchise and must rely on new launches and pipeline progression to restore profit growth over time.

VYVANSE Generic Erosion Forces Revenue Guidance Cut

Management was explicit that the downgrade to revenue guidance was driven by stronger‑than‑expected generic competition to VYVANSE in the U.S. The magnitude and speed of erosion have outpaced initial assumptions, forcing the company to recalibrate expectations for the current fiscal year to a low single‑digit decline in sales at constant exchange rates. The call reinforced that VYVANSE will remain a material drag in the near term, and that management’s response focuses on protecting core earnings and accelerating the ramp‑up of growth and launch products.

TAKHZYRO Growth Slows Under Competitive and Policy Pressure

Hereditary angioedema therapy TAKHZYRO, previously one of Takeda’s standout growth engines, saw its momentum slow to 2.4% growth at constant exchange rates year‑to‑date. Management attributed the softer trajectory primarily to new competitors in the U.S. market and to the negative impact of the Medicare Part D redesign. While TAKHZYRO remains an important asset, the commentary underscored that competitive dynamics and U.S. policy changes are constraining its ability to deliver the kind of high‑teens growth that investors once associated with the brand.

Plasma Therapies and China Exposure Weigh on Outlook

In plasma‑derived therapies, albumin returned to modest growth of 1.3% but fell short of internal expectations owing to weaker demand in China and product reallocation pressures. Management cautioned that certain components of the plasma franchise may end the year below forecast. The China softness notably adds a macro and geographic dimension to Takeda’s challenges, highlighting that not all of its headwinds are product‑specific or U.S. policy‑driven.

IVIG Hit by Medicare Part D Redesign

Intravenous immunoglobulin (IVIG) sales were another casualty of the Medicare Part D overhaul in the U.S., with management citing the policy change as a key factor behind short‑term weakness. The company expects some normalization in the fourth quarter as the market adjusts, but acknowledged that the redesign is a clear headwind in the near term. For investors, the IVIG performance adds to the evidence that U.S. reimbursement reforms are creating friction across several parts of Takeda’s portfolio.

ENTYVIO Faces Long-Term IRA Pricing Risk

Despite its current growth momentum, ENTYVIO is now on the radar for future U.S. price pressure after being selected for the third cycle of price negotiations under the Inflation Reduction Act. Management emphasized the uncertainty around the ultimate magnitude of any mandated price cut from 2028 and how it might affect previously communicated peak sales expectations. While the impact is several years out, the selection introduces a new layer of long‑term pricing risk around one of Takeda’s most important franchises, which investors will need to factor into their valuation models.

Higher R&D and Launch Spend Set to Pressure Margins

Looking ahead, Takeda signaled that operating expenses will rise as it ramps investments behind the three imminent product launches and other late‑stage programs. Management plans to partially offset this increased R&D and launch spend through efficiency initiatives, but conceded that the near‑term OpEx load will weigh on margins. The trade‑off is deliberate: sacrificing some short‑term margin comfort to support the commercialization of new assets that are expected to underpin growth later in the decade.

Impairment Highlights Ongoing Asset-Level Risk

Reported operating profit of JPY 422.4 billion for the period was up a modest 1.2% year‑on‑year, aided by one‑off factors but also burdened by an impairment booked in the second quarter related to cell therapy intangible assets. Management acknowledged that such asset‑level impairments are an inherent risk in a research‑driven portfolio and could remain a source of volatility in reported results. For shareholders, this underscores the difference between Takeda’s more stable core metrics and the lumpier nature of reported profit under IFRS.

Guidance and Outlook: Navigating a Transition Year

Takeda’s updated guidance frames the current fiscal year as a managed transition rather than a growth year. The company now expects a low single‑digit revenue decline at constant exchange rates, with full‑year revenue guided to JPY 4.53 trillion, reflecting the heavier‑than‑expected VYVANSE erosion. Yet core operating profit guidance remains at JPY 1.15 trillion and core EPS at JPY 486, supported by FX tailwinds, cost discipline, and steady growth in launch products. Year‑to‑date, revenue of just over JPY 3.4 trillion was down 3.3% (2.8% at CER), core OP of JPY 971.6 billion was down 3.4%, and core EPS stood at JPY 428. Management’s upgraded adjusted free cash flow outlook, off the back of JPY 625.9 billion generated year‑to‑date, signals confidence that Takeda can fund its expanding pipeline and upcoming launches while weathering near‑term revenue and pricing pressures.

In sum, Takeda’s earnings call painted a picture of a company in transition: headline revenues and profits are under pressure from loss of exclusivity, competition, and policy shifts, but the underlying engine—anchored by a strengthening growth portfolio, multiple successful Phase III programs, and solid free cash flow—appears robust. The near‑term will likely be defined by top‑line headwinds and rising launch spend, yet management’s ability to hold core earnings guidance and upgrade cash flow expectations suggests that Takeda is absorbing these shocks from a position of relative strength, setting the stage for a potentially more attractive growth profile once new launches scale and legacy erosion moderates.